Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Featured

Tara Graff, DO, Talks About Acalabrutinib and How the CLL Treatment Landscape has Evolved

In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.

Dr Burger Discusses Outcomes Following RESONATE-2 and iLLUMINATE Studies

Jan A. Burger, MD, PhD, MD Anderson Cancer Center, discusses "Outcomes of First-Line Ibrutinib in Patients with CLL/SLL and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated…

Real-World Outcomes of First-Line Ibrutinib vs CIT for CLL

Lori Leslie, MD, discusses clinical outcomes among real-world patients with CLL given first-line therapy with ibrutinib or chemoimmunotherapy (CIT).

Anthony Mato, MD, Talks Real-World Biomarker Testing for CLL, SLL

Dr. Mato highlights data from “Real-World Prognostic Biomarker Testing, Treatment Patterns and Dosing Among 1461 Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)…

Othman Al-Sawaf, MD, Discusses Results From the Phase 3 CLL14 Trial

Othman Al-Sawaf, MD, University Hospital of Cologne, Germany, discusses highlights from the phase 3 CLL14 trial, which looked at venetoclax plus obinutuzumab therapy for chronic lymphocytic leukemia…

John Allan, MD, Talks Long-Term Efficacy of First-Line Ibrutinib for TP53-Mutated CLL

In this video, John Allan, MD, Weill Cornell Medicine, discusses long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia with 4 years of follow-up in patients with TP53…

Venetoclax Monotherapy Yields Deep Responses, Manageable Safety in CLL

Arnon P. Kater, MD, PhD, discusses results from the phase 3b VENICE I trial, which evaluated the efficacy of venetoclax in patients with relapsed/refractory CLL.

Ibrutinib Plus Venetoclax Yields High Rates of Undetectable MRD in CLL

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses the results of the MRD cohort of the CAPTIVATE trial, a multicenter phase 2 trial evaluating ibrutinib plus venetoclax in CLL and SLL.

Acalabrutinib Demonstrates Favorable Safety and Efficacy in Relapsed/Refractory CLL

Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.